Study of the combination gemcitabine and trastuzumab in the treatment of HER2+metastatic breast cancer

被引：0
|
作者：
Menjon-Beltran, S. [1 ]
Olivencia-Dueso, R. [1 ]
Gonzalez-Jimenez, E. [1 ]
Titos, M. J. [1 ]
机构：
[1] Hosp Univ Virgen Nieves, Unidad Ginecol Oncol, Granada, Spain
来源：
BREAST CANCER RESEARCH | 2007年 / 9卷 / 01期
关键词：
Gemcitabine; Trastuzumab; Clinical Benefit; Stable Disease; Metastatic Breast Cancer;
D O I：
10.1186/bcr1717
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Study of the combination gemcitabine and trastuzumab in the treatment of HER2+ metastatic breast cancer
    S Menjón-Beltrán
    R Olivencia-Dueso
    E González-Jiménez
    MJ Titos
    Breast Cancer Research, 9
  • [2] Bevacizumab plus trastuzumab for treatment of HER2+metastatic breast cancer
    De Amuriza Chicharro, N.
    Gastalver Martin, C.
    Goyache Goni, M. P.
    Cortijo Cascajares, S.
    Garcia Munoz, C.
    Ferrari Piquero, J. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 984 - 985
  • [3] A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+metastatic breast cancer progressing on trastuzumab therapy
    O'Shaughnessy, J.
    Blackwell, K. L.
    Burstein, H.
    Storniolo, A. M.
    Sledge, G.
    Baselga, J.
    Koehler, M.
    Laabs, S.
    Florance, A.
    Roychowdhury, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Phase I/II trial of ruxolitinib in combination with trastuzumab in HER2+metastatic breast cancer (MBC)
    Kalinsky, Kevin
    Lee, Shing
    Tiersten, Amy
    Makower, Della F.
    Cigler, Tessa
    Franks, Lauren
    Mundi, Prabhjot
    Chi, Dow-Chung
    Blumberg, Lauren
    Sender, Naomi
    Galazyn, Magdalena
    Hosi, Kristina
    Goel, Anupama
    Klein, Paula
    Andreopoulou, Eleni
    Sparano, Joseph
    Crew, Katherine D.
    Califano, Andrea
    Silva, Jose
    Hershman, Dawn L.
    CANCER RESEARCH, 2020, 80 (04)
  • [5] Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+metastatic breast cancer
    Niculescu-Duvaz, Ion
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2010, 12 (03) : 350 - 360
  • [6] The association of centromere amplification and response to trastuzumab in HER2+metastatic breast cancer
    Andrieu, Charlotte
    Al-Sultan, Dalal
    Ivers, Laura
    Pina, Jose Javier Berenguer
    Skrobo, Darko
    Ballot, Josephine
    Eustace, Alex J.
    Gullo, Giuseppe
    Crown, John
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Trastuzumab and vinorelbine or taxane chemotherapy for HER2+metastatic breast cancer: The TRAVIOTA study.
    Burstein, H. J.
    Keshaviah, A.
    Baron, A.
    Hart, R.
    Lambert-Falls, R.
    Marcom, P. K.
    Gelman, R.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 40S - 40S
  • [8] N0337: Phase II study of capecitabine in combination with vinorelbine and trastuzumab for the first or second treatment of HER2+metastatic breast cancer
    Tan, W.
    Allred, J.
    Salim, M.
    Flynn, P.
    Kugler, J. W.
    Stella, P. J.
    Wiesenfeld, M.
    Bernath, A. M.
    Fitch, T. R.
    Perez, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With HER2-Overexpressing Metastatic Breast Cancer
    Yardley, Denise A.
    Burris, Howard A., III
    Hanson, Sarah
    Greco, F. Anthony
    Spigel, David R.
    Barton, John
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2009, 9 (03) : 178 - 183
  • [10] Phase 3 study of maintenance treatment of tucatinib or placebo in combination with trastuzumab and pertuzumab in HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)
    Muller, V
    Hamilton, E.
    O 'Sullivan, C.
    Martin, M.
    Sohn, J.
    Tryfonidis, K.
    Santarpia, L.
    Yang, S.
    Dieras, V
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 106 - 106
12345